Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SOLARA

SOLARA

Solara Active Pharma Sciences Limited
Micro-capPharma ↗

What the six lenses say about SOLARA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹697.0
2026-09-08
VWAP · 1Y anchor
₹582
+19.8% from VWAP
P/E · TTM
-340.0×
TTM EPS ₹-2.0
52-week range
100%
position low→high
RSI(14)
76
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SOLARA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.5
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD9100›

The actual numbers

Price vs VWAP (1y)+19.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+26.7%
Price vs 50-EMA+20.8%
RSI(14)76
RS vs Nifty 500 · 3M+28.4%
RS vs sector · 3M+22.3%
52-week range100%
Volume vs 30d avg1.41×
Volume vs 60d avg1.64×
ATR(14) · volatility36.2
Bollinger width · vol contraction0.364
FundamentalD221›

The actual numbers

Return on equity (ROE)-0.6%
Operating margin6.4%
Net margin-0.5%
Revenue growth · YoY+6.6%
EPS growth · YoY-518.4%
Debt / equity0.55×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)-340.0×
TTM EPS₹-2.0
52-week range100%
CatalystD535›

The actual numbers

Earnings & momentum29
Capital actions13
Governance127

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding42.0%
Delivery · 30d avg45.7%
Up/down-day asymmetry-1.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D4 ) ÷ 2 = 6.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 6.5/10
Conviction score95/100›
TechnicalD9›
FundamentalD2›
ValuationD1›
CatalystD5›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+9.6pp
+11.4pp
+39.9pp
+30.0pp
+54.6pp
+6.6pp
Nifty 500
Broad-market baseline
+9.5pp
+11.4pp
+38.8pp
+28.4pp
+48.8pp
+1.4pp
Sector
Own-sector index
—
—
+36.0pp
+22.3pp
+35.7pp
-19.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SOLARA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
697.05+57.90

Relative strength

RS vs baseline · rebased to 100

SOLARA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
90.23+7.84

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)363347300273319314349387
↳ change QoQ—-4.6%-13.4%-9.1%+16.9%-1.8%+11.3%+11.0%
EBITDA (₹cr)4262594557353758
EBITDA margin11.7%17.8%19.7%16.6%17.9%11.1%10.7%14.9%
PAT (₹cr)-1388-211-10-1710
↳ change QoQ—+159.5%+1.0%-126.0%+601.0%-196.0%-72.6%+155.1%
Net margin-3.7%2.3%2.7%-0.8%3.3%-3.2%-5.0%2.5%
EPS (₹)-3.502.542.03-0.582.91-2.79-4.822.65
D/E————————
YoY growth · Mar '26Revenue +41.9% YoYPAT +557.1% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 28 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Aug '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Monitoring Agency Report
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Statement of deviation(s) or variation(s) under Reg. 32
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 23 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 16 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma